Potency test for vaccine formulations

ABSTRACT

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional application of U.S. Ser. No.13/759,620, filed on Feb. 5, 2013, now U.S. Pat. No. 8,802,378 B2, whichis a Continuation application of non-provisional application U.S. Ser.No. 12/875,618, filed on Sep. 3, 2010, now U.S. Pat. No. 8,546,149 B2,that claims priority under 35 U.S.C. §119 (e) of provisional applicationU.S. Ser. No. 61/377,485, filed on Aug. 27, 2010. The contents of whichare hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

The invention relates to certain methods for the determination of anantigen content of a first antigen in a mixture comprising two or moreantigens. The invention also relates to a potency test for an antigen ina combination vaccine.

BACKGROUND OF THE INVENTION

Vaccines comprising a combination of protective antigens derived fromdifferent pathogenic organisms have multiple obvious benefits, both forthe recipient—and manufacturer of the vaccine. In particular,combination- or multivalent vaccines offer increased ease ofadministration and greater comfort and convenience to the patient byreducing the number of injections required and possibly the number ofattendances. They are also more economical to manufacture and administerbecause of savings on processing of combined bulk material, containers,packaging, distribution and injection equipment.

In the field of human health combination vaccines are often used in thecontext of infant vaccination. Combination vaccines such as DTP(diphtheria, tetanus and pertussis), with or without inactivatedpoliomyelitis and MMR (measles, mumps and rubella) have been in use formany years and new antigens have been added to this combination duringthe last years.

Also in the field of animal health combination vaccines are commonlyused. In particular vaccines of poultry, swine, ruminants and companionanimals are, more often than not, based on a combination of multipleantigens. Examples of such vaccines are combination vaccines againstcanine distemper, hepatitis, parainfluenza type 2, parvovirus,leptospira and rabies virus for dogs, rotavirus, coronovirus and E. colifor cattle, Newcastle disease virus, infectious bronchitis, infectiousbursal disease, swollen head syndrome and egg drop syndrome for poultry.

A vaccine batch may be released for sale only after a license ormarketing authorization has been issued. In addition, each subsequentbatch of such an authorized vaccine batch has to be formally released incompliance with the rules of a state or number of states concerned. Thisrelease may be permitted on the authority of the manufacturer aftersatisfactory completion of the prescribed batch testing. Therefore, toguarantee that each and every batch of vaccine will have its intendedeffect, a manufacturing process of consistent quality has to be inplace, and the application of a potency test is an essential element ofsuch a process.

Presently, different test methods, such as assays of physiochemicalproperties, antigenicity, immunogenicity, infectivity and protectionagainst infection or disease, are used to measure vaccine potency. Theirapplication depends on the nature of the vaccine antigens and thepurpose of the test. In live vaccines, potency can be based on thenumber of organisms present in the vaccine (titre). In the case ofinactivated vaccines, the potency is often determined by measuring theimmune response in the target animal species or in another species, e.g.mice or rats. Alternatively, the potency of an inactivated vaccine canbe based on its antigenicity by measuring the quantity of the antigenpresent (antigen mass), using immuno assays that employ specificantibodies, such as an ELISA (enzyme-linked immunosorbent assay).

BRIEF SUMMARY OF THE INVENTION

The inventors have identified an unexpected interaction between aspecific antigen and another component in a combination vaccine aftermixing the compositions comprising the antigen and the other component,respectively. Accordingly, the invention provides methods for thedetermining the antigen content of a first antigen in a mixturecomprising two or more antigens. The invention also provides a potencytest for an antigen in a combination vaccine. The methods providedherein further allow the determination of the antigen content in amixture additionally comprising antibodies that are capable of bindingwith that antigen.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts a titration of a monovalent (♦) vaccine containing PCV-2and a bivalent (▪) vaccine containing PCV-2 and M. hyo. demonstratingthe existence of PCV-antibody complexes.

FIG. 2 shows the influence of acid concentration on viralantigen-antibody complexes by varying the ratio (v/v) between 0.1Mcitric acid and monovalent (♦) or bivalent (▪) vaccine. a) Recovery (%)was based on untreated monovalent vaccine measured by ELISA as describedin Example 1 below. b) Ratio (v/v) between acid and vaccine during theacid treatment as described in Example 4 below.

FIG. 3 shows the influence of the time of treatment on the PCV units/mlfor the monovalent (♦) and bivalent (▪) vaccines. a) Units/ml determinedby ELISA as described in Example 1.

FIG. 4 shows the influence of pH assessed by acid treatments atdifferent pH's. a) 5 independent PCV batches were each mixed with oneout of two, [A, B] independent M. hyo batches. All 10 preparations wereacid treated as described in Example 4 below, either with 0.1M citricacid or with 0.1M citric acid adjusted with sodium acetate to pH 2, 3,4, or 5, or with buffer (C=control). The concentrations are expressed aspercentages of the concentrations obtained by the standard treatment(0.1M citric acid, pH 1.5). Data are shown as the mean±Std of the 5 PCVbatches combined either with M. hyo batch A (♦) or B (▪).

DETAILED DESCRIPTION OF THE INVENTION

Although, pharmacopeial requirements for the individual antigencomponents of combination vaccines provide a starting point to establisha relevant and effective potency test, problems resulting frominteraction between the various components in more complex combinationvaccines are well known (Vidor, J. Comp. Path. 137, 62-66, 2007;Sesardic et al., Biologicals 27, 177-181, 1999). Each combinationvaccine is comprised of a unique aggregation of active componentsexcipients, and residual substances. Any of these materials mayinterfere with accurate measurement of the potency of a given activecomponent. Interference with an antigen's antigenicity or immunogenicitymay be caused by the nature of the other antigens present, theirquality, quantity or ratio, the adjuvant, preservative, stabilizer, pH,isotonicity of the vaccine etc.

Surprisingly, however, it has been found that the antigenicity of afirst antigen, in a mixture of a composition comprising the firstantigen and a composition comprising a second antigen, is affected bythe presence of antibodies that bind to this first antigen therebyforming an antigen-antibody complex and that these antibodies canoriginate from the composition comprising the second antigen. Examples 1and 2 show the problem that an antigen can be inefficiently detected inmixtures of compositions comprising different antigens and thatantigen-antibody complexes can be formed in such mixtures wherein theantibodies orginate from a composition different from the compositioncomprising the antigen to be detected. Moreover, it has been found thatthe dissociation of the antigen-antibody complexes results in a recoveryof the antigenicity of the first antigen. The presence of suchinterferring antibodies can be explained by the necessity of culturingcertain micro-organisms (second antigen) in vitro in the presence ofserum derived from animals and that these animals from which the serumis harvested are infected by a micro-organism that evokes antibodiesagainst the first antigen. The interference of these antibodies with theantigenicity of the first antigen in the mixture affects thequantification of the first antigen in immunoassays, such as potencytests for releasing vaccine batches for sale.

Briefly, the invention relates to a method for the determination of anantigen content of a first antigen in a mixture of at least acomposition comprising the first antigen and a composition comprising asecond antigen.

The invention relates to such a method wherein the compositioncomprising the second antigen also comprises antibodies that are capableof binding with the first antigen.

The invention also relates to a method for the determination of anantigen content of a first antigen in a mixture of at least acomposition comprising the first antigen and a composition comprising(i) a second antigen and (ii) antibodies that are capable of bindingwith the first antigen, the method comprising the steps of:

-   -   A dissociating antigen-antibody complexes in the mixture, formed        between the first antigen and the antibodies, and    -   B determining the antigen content of the first antigen by means        of an immunoassay.

The design of the immunoassay may vary and can be similar to thoseimmunoassays which are commonly used in the art for quantifying viral-or bacterial antigens in samples. For example, the assay may be basedupon a competition- or direct reaction. Furthermore, protocols may usesolid supports, such as microtitre plates. The detection of the antigenmay involve the use of (directly or indirectly) labelled antibodiesspecific for the first antigen (detection antibodies) and the labels maybe enzymes, fluorescent-, chemilumiscent-, radioactive- or dyemolecules. The detection antibodies may be monospecific polyclonal ormonoclonal antibodies. Typical immunoassays to be used in a methodaccording the invention are described in standard laboratory text books,such as, Antibodies: A Laboratory Manual, eds.: Harrlow and Lane, ColdSpring Harbor Laboratory Press, 1988. Examples of such tests areagglutination assays, ELISA and AlphLISA.

The antigens may be any kind of antigen, but preferably are derived froma micro-organism pathogenic to humans or animals. In particular, theantigens are derived from a virus or bacterium.

In general, the term antigen refers to a composition of matter thatcomprises at least one epitope that can induce, stimulate or enhance animmune response when administered to a human or animal.

The antigen can be the whole pathogen, preferably in an inactivated orattenuated form, an extract of the pathogen or an immunogenic protein ofthe pathogen.

More preferably, the antigen is an immunogenic protein that is expressedin and recovered from in vitro cultured cells.

In particular, the first antigen may be an antigen of a pathogen thatinduces (by natural exposure or by vaccination) pathogen specificantibodies of high prevalence in a particular animal species.

For example, this pathogen may be selected from the group existing ofporcine circovirus type 2 (PCV-2), Erysipelothrix rhusiopathiae,bluetongue virus, border disease virus, neospora canium, turkeycoronavirus and foot-and-mouth disease virus.

In particular, the second antigen may be an antigen of a pathogen thatdepends for its culturing in vitro on serum from a particular animalspecies.

For example, this pathogen may be selected from the group consisting ofMycoplasma, Lawsonia, Leishmania, Babesia, Toxoplasma and Neospora.

In a particularly preferred method according to the invention the firstantigen is a porcine circovirus type 2 (PCV-2) antigen, in particular aPCV-2 ORF2 antigen.

The PCV-2 ORF2 antigen to be used in a method according to the inventionrepresents a protein of about 30 kDa and is used as an active componentin PCV2 vaccines commercially available, such as Porcilis PCV®(Intervet/Schering-Plough Animal Health, Netherlands).Ingelvac®CircoFLEX (Boehringer Ingelheim Vetmedica Inc., USA) andSuvaxyn PCV® (Fort Dodge Animal Health, USA). PCV-2 ORF2 to be used in amethod according to the invention can, for example, be obtained from invitro cultured insect cells infected with recombinant baculoviruses thatare transformed with a gene encoding the PCV-2 ORF2 protein and thatexpress the protein in the insect cells (Fort et al., Vaccine 27,4031-4037, 2009; Nawagitgul et al., J. Gen. Virol. 81, 2281-87, 2000 andFachinger et al., Vaccine 26, 1488-99, 2008).

In another preferred method according to the invention as describedabove the second antigen is Mycoplasma hyopneumoniae (M. hyo) and thecomposition comprising the second antigen additionally comprises serum,in particular serum antibodies directed against the first antigen andcapable of binding thereto.

In a particularly preferred method according to the invention, the firstantigen is a PCV-2 antigen, preferably, a PCV-2 ORF2 protein and thesecond antigen is a M. hyo antigen, preferably a M. hyo bacterin.

In essence, the method of the invention comprises a pre-treatment of themixture comprising the antigen to be analysed before the antigen contentthereof is determined in a conventional immunoassay. This pre-treatmentinvolves the dissociation of the antigen-antibody complexes formedbetween the first antigen and antibodies that are capable of bindingwith this first antigen. The inventors have shown that such adissociation step makes the first antigen available again for thequantification in an immunoassay.

Both in the field of human- and animal health it is common tomanufacture combination vaccines comprising more than two differentantigens. In particular, in the field of animal health combinationvaccines comprising three to six different antigens is not unusual.Therefore, the method of the present invention also contemplates thedetermination the antigen content of a first antigen in a mixture thatis composed of more than two compositions comprising different antigens,in particular three to six compositions.

A particularly suited method according to the invention as describedabove comprises the well known ELISA as the immunoassay.

In an exemplifying ELISA to be used in a method according to theinvention as described above, the following steps are used:

-   -   coating the wells of an ELISA micro-titre plate with a capture        antibody, preferably a monoclonal antibody, directed to the        first antigen,    -   incubating (serial dilutions of) a test sample of the mixture to        be analysed, alongside a (series of dilutions of a) reference        standard, and the appropriate control solutions, in the wells,    -   incubating the wells with a detecting antibody, preferably a        monoclonal antibody, directed to the first antigen. The        detecting antibody may be directly, preferably indirectly,        labelled with an enzyme. Preferably, the detecting antibody is a        biotinylated antibody.    -   in case of indirect labelling, incubating the wells with an        enzyme-conjugate that binds the enzyme to the antibody.        Preferably, the conjugate is an avidin-enzyme conjugate,    -   adding an enzyme substrate solution to the wells, followed by        chromophoric detection.        The amount of antigen in the test sample is calculated against        the reference standard. A more detailed ELISA procedure is        described in the Examples.

Typically, the enzyme used herein is horseradish peroxidase and theenzyme substrate is TMB (3,3′,5,5′ tetramethylbenzidine).

The method according to the invention can be used to determine thepotency of a certain antigen in a mixture at various stages in theprocess of the manufacturing of a combination vaccine. For example, themethod can be applied on a sample of a mixture that is composed of twoor more compositions comprising the antigens, directly harvested fromthe culture vessel.

Alternatively, the compositions comprise the antigens in a furtherpurified form, e.g. by means of centrifugation, filtration orprecipitation.

Ideally, the potency of an antigen in a vaccine is determined in thefinal vaccine formulation, in its ready-to-use form. A ready-to-usevaccine formulation comprises all the components and excipients that arenecessary and sufficient to allow the vaccine to be used in the field.In particular, a ready-to-use vaccine comprises two or more antigens, anadjuvant, a stabilizer and a preservative.

Therefore, in a preferred method according to the invention as describedabove, the mixture is a ready-to-use vaccine formulation.

In a particularly preferred method according to the invention asdescribed above, the mixture is incubated with an acid solution todissociate the antigen-antibody complexes.

In this pre-treatment step the mixture is diluted with the acid(dissociation) solution, optionally as a buffer, such as a PBS buffer orTris-HCl buffer, and incubated to allow the antigen-antibody complexesto dissociate. The incubation can take place at room temperature underlight shaking. After the pre-treatment step a sample of the acid treatedmixture is analysed in an immunoassay, preferably by adding a sample ofthe acid treated mixture to an ELISA plate and further testing asdescribed above.

It has been found that the nature of the acid solution is not critical.The examples show that a variety of acid solutions are able todissociate the antigen-antibody complexes, and, at the same time leavingthe antigenicity of the antigen unaffected.

In yet a further preferred method according to the invention asdescribed above the acid solution is an acetic acid solution, sulphuricacid solution, hydrochloric acid solution or citric acid solution,preferably the acid solution is a citric acid solution.

In an alternative method according to the invention as described abovethe acid solution is a buffer.

The incubation time of the mixture with the acid solution may vary withthe nature of the antigen in the antigen-antibody complex. Preferably,the incubation time is at least 8 hours, preferably 8-18 hours, morepreferably 16-18 hours with a ready-to-use vaccine.

Thus, in another preferred method according to the invention asdescribed above the mixture is incubated with an acid solution for atleast 8 hours.

It has also been found by the inventors that the ratio (v/v) between theacid solution and the mixture may affect the level of dissociation ofthe antigen-antibody complexes. Good results have been obtained with aratio (v/v) between the acid solution and the mixture of at least 25, inparticular with a ratio (v/v) of 25-75, more in particular with a ratio(v/v) of 25-50.

Thus, in another preferred method according to the invention asdescribed above the mixture is incubated at a ratio (v/v) between theacid solution and the mixture of at least 25, preferably 25-75, morepreferably 25-50.

In a further preferred method according to the invention as describedabove the acid solution has a pH of 1.0-3.0, preferably of 1.5 (±0.2).

Optionally, in a method according to the invention as described above,after the incubation of the mixture with the acid solution, but beforethe analysis thereof in the immunoassay, the pH of the acid treatedmixture is elevated to a more neutral pH, preferably 5-7. This can bedone by adding a base solution or a buffer to the acid treated mixture.Appropriate solutions for this purpose are sodium hydroxide, phosphate-or Tris buffer.

The invention also is directed to a method for the determination of anantigen content of a PCV-2 antigen in a mixture of at least acomposition comprising the PCV-2 antigen and a composition comprising aM. hyo antigen, the method comprising the steps of,

-   -   A mixing the two compositions, and    -   B determining the antigen content of the PCV-2 antigen by means        of an immunoassay,        characterized in that the M. hyo antigen is obtained from a        culture that comprises non-swine serum.

In particular, the M. hyo antigen is obtained from a culture thatcomprises bovine-, horse, or sheep serum (Ahmad et al., Avian diseases32, 519-526, 1988; Ramirez et al., 178, 149-152, 2008).

In a further alternative method the composition comprising the secondantigen and the antibodies directed against the first antigen issubjected to a separation of these two components after which thecomposition comprising only the second antigen is mixed with thecomposition comprising the first antigen. Subsequently, the antigencontent of the first antigen is determined by means of the immunoassay.

Therefore, the invention also relates to a method for the determinationof an antigen content of a first antigen in a mixture of at least acomposition comprising the first antigen and a composition comprising asecond antigen, the method comprising the steps of,

-   -   A separating the second antigen from antibodies that are capable        of binding with the first antigen in a composition comprising        the second antigen and the antibodies,    -   B mixing the second antigen with a composition comprising the        first antigen, and    -   C determining the antigen content of the first antigen in the        mixture by means of an immunoassay.

The separation of the second antigen from e.g. medium in which theantigen was cultured can be carried out by routine methods available forthis purpose. For example, in case the second antigens are bacteria,these can be separated by means of centrifugation at 15.000 g for 10minutes.

It is also possible that the separation is routinely effected by meansof immuno-depletion wherein the antibodies are captured with a ligandthat exhibits affinity for the antibodies, followed by a separation ofthese ligand-antibody complexes from the second antigen. Ligandscommonly used for this purpose are Protein-G, Protein-A or antibodiesdirected against the antibodies to be separated. Usually, these ligandsare bound to a solid phase (e.g. Sepharose 4B) that facilitate theseparation of the antigen from the antibodies.

Therefore, in a preferred embodiment of this method the separation iseffected by means of a centrifugation- or immuno-depletion step.

In further preferred embodiments of this method the antigens to be usedand the immunoassay to be applied herein are the same as those definedabove.

The invention is directed also the any of the methods as describedabove, further characterized in that the method is a potency test of acombination vaccine.

A potency test of a vaccine is defined as a test to determine thespecific ability or capacity of the vaccine, as indicated by appropriatelaboratory tests or by adequately controlled clinical data obtainedthrough the administration of the vaccine in the manner intended, toeffect protective immunity. As such, the potency test used in thisinvention is a test applied on a batch of vaccine produced forcommercial purpose to provide data that show whether the batch ofvaccine meets critical assay parameters.

In a preferred potency test according to the present invention theimmunoassay is an ELISA (as outlined above) and the critical assayparameter is the antigen mass of the first antigen in the mixtureexpressed in ELISA-units (EU). The EU relate to an internal standard ofthe antigen that, in turn, correlates to protective immunity in a targetanimal.

EXAMPLES Example 1 Influence of M. hyo composition on the quantificationof PCV-2 antigen in ELISA

As a means of quality control concentrations of PCV2 containing vaccinesare determined in a sandwich ELISA based on two monoclonal antibodiesspecific for PCV2. However, as compared with monovalent vaccines,concentrations distinctly below the expectations were measured inbivalent vaccines comprising PCV2 and Mycoplasma hyopneumoniae (M. hyo)preparations.

A combination vaccine containing M. hyopneumoniae and PCV2 antigens wasproduced as follows: M hyopneumoniae whole cell antigen is produced byculturing M. hyopneumoniae strain 11 in a broth medium based on themedium originally described by Friis (Nord. Vet.-Med., 27, 337-339,1975). This is a complex medium that contains yeast extract, serum andvarious extracts of porcine and bovine origin. At the end ofcultivation, the bacterial cells were inactivated and the whole culturewas concentrated at least 10 times by ultrafiltration and used for theformulation of the vaccine. The PCV2 ORF2 antigen was producedrecombinantly using Baculo virus expression in Sporoptera frugiperda(Sf21) cells that were cultured in medium suitable for insect cellgrowth. After harvesting of the viral fluids and inactivation of thevirus particles, the PCV2 ORF2 antigen were concentrated bycentrifugation and used for vaccine production. To prepare thecombination vaccine, the two antigens were mixed, diluted with bufferand blended with the w/o adjuvant Xsolve (vitamin E acetate/light liquidparaffin/Tween 80) at a ratio of 70/30 (v/v).

A summary of the results from mixing the PCV2 preparations with placeboor several batches of M hyo preparations are shown in Table 1.

TABLE 1 Influence of Mhyo on the quantification of PCV by ELISA PCVbatch #1 PCV batch #2 PCV batch #3 recovery recovery recovery ELISAunits^(a)) (%)^(b)) units (%) units (%) — 2961 100 2765 100 2482 100 Mhyo 1109 37.5 1607 58.1 1627 65.6 batch # 1 M hyo 960 32.4 1641 59.31838 74.1 batch # 2 M hyo 939 31.7 2171 78.5 1983 79.9 batch # 3^(a))PCV concentrations are determined by comparing titrations ofreference preparation and test samples by ELISA. To this end 96 wellNunc MaxiSorp plates are incubated over night at 4° C. with an optimalconcentration of monoclonal antibody 3/1B4-INT diluted in carbonatebuffer pH 9.6., serial dilutions of references and test samples, dilutedin PBS containing BSA and Tween (EIA buffer), are incubated for 1 hourat 37° C. Followed by a wash step, an optimal concentration of biotinlabeled monoclonal antibody 5/6H12-INT diluted in EIA buffer isincubated for 1 hour at 37° C. Followed by a wash step, an optimalconcentration of HRP-labeled avidin diluted in EIA buffer is incubatedfor 0.5 hour at 37° C. Followed by a wash step, an optimal concentrationof TMB substrate is incubated for 15 minutes and stopped by sulfuricacid and optical densities are measured with an ELISA reader.Concentrations are calculated by the 4PL method. Values are expressed asELISA units (average of 3 measurements). ^(b))Standard deviation (n = 3)^(c))Recovery (%) as compared with vaccines containing the same amountof PCV in the absence of M hyo.

These results show that in vaccines containing PCV and M hyo, M hyonegatively affects the detectability of the PCV-2 antigen in thecombination vaccine and that the degree of recovery (31%-80%) depends onthe combination of the mixed PCV-2 and M hyo preparations.

Example 2 Identification of Antigen-Antibody Complexes

Antigen-antibody complexes in bivalent PCV-2/M. hyo vaccines have beendemonstrated by a sandwich ELISA. Complexes between PCV-2 antigen andpolyclonal porcine anti-PCV-2 antibodies are captured by monoclonalanti-PCV-2 antibodies coated to microtiter plate wells and detected withenzyme labelled anti-porcine IgG conjugate. FIG. 1 shows a titration ofa monovalent vaccine containing PCV-2 and of a bivalent vaccinecontaining PCV-2 and M. hyo. The ELISA was performed as described inExample 1 with the exception that instead of a labelled monoclonalanti-PCV antibody, complexes were detected with an enzyme labelledanti-porcine IgG conjugate. Data points represent the average oftriplicates. The results demonstrate that a) the M. hyo preparationscontain porcine anti-PCV-2 antibodies and b) that these antibodies formcomplexes with PCV-2.

The most likely explanation for reduced detectability of PCV-2 inbivalent vaccines is that the porcine anti-PCV-2 antibodies block PCV-2epitopes relevant in the PCV-2 sandwich ELISA. PCV-2 antibodies werefound to be present in commercial swine serum batches necessary in themedium used in the media for culturing M. hyo for manufacturing vaccineson a commercial scale.

Example 3 Attempts to Reverse the Inhibitory Effect of M hyo

Procedures to reverse the inhibitory effect of M hyo preparations weretested by treating two vaccine preparations containing the same amountof PCV-2 but lacking (monovalent vaccine) or containing (bivalentvaccine) M. hyo. The sandwich ELISA, as described in Example 1, wasperformed either in the presence of various concentrations of reagents(SDS, Tween Triton, Na deoxycholate, Urea) in the diluent. Furthermore,supernatants and pellets of ammonium sulphate (AS) precipitations(without or in the presence of Triton) and size separated fractions (inthe presence of Triton) were assayed.

TABLE 2 Effect of vaccine treatments concentration recovery (%)treatment range monovalent bivalent — 100   33.9 SDS (%) 0.25-2   72-16724-48 Tween (%)  0.1-5.4 106-116 26-30 Triton X100 (%)  0.1-5.4 113-11932-35 Na deoxycholate. (%)  0.1-5.4 113-129 31-44 Urea (M)  1-8  0-101 0-47 AS precipitation (%), 2.5-80 ND  3-37 supernatant AS precipitation(%), 2.5-80 ND 0.2-7.6 pellet 2% SDS, AS precipitation 2.5-80 2.7-16 0.1-25  (%), supernatant 2% SDS, AS precipitation 2.5-80 6.6-17  0.4-16 (%), pellet 10% Triton X100, 56 9 filtration >300 kD 10% Triton X100,  31 filtration <300 kD

The results of Table 2 show that none of the treatment left themonovalent vaccine unaffected and reversed the inhibitory effect of Mhyo.

Example 4 Effect of Acid Treatment on Viral Antigen-Antibody Complexes

The potential of acid treatments has been evaluated. One part (volume)of vaccine is mixed with 49 parts of 0.1 M citric acid (diluted indistilled water) and incubated over night at room temperature with lightshaking

Representative results generated with a developed standard procedure areshown in Table 3.

TABLE 3 Effect of acid treatment PCV batch #1 PCV batch #2 PCV batch #3Acid recov- recov- recov- treat- ery ery ery ment^(c)) units^(a))(%)^(b)) units (%) units (%) — − 2961 100 2765 100 2482 100 + 3273 1002941 100 3430 100 M hyo − 1109 37.5 1607 58.1 1627 65.6 batch # 1 + 306193.5 2844 96.7 3110 90.7 M hyo − 960 32.4 1641 59.3 1838 74.1 batch #2 + 3124 95.4 2760 93.8 2950 86.0 M hyo − 939 31.7 2171 78.5 1983 79.9batch # 3 + 3247 99.2 2875 97.8 3468 101.1 ^(a))-^(c))as described inExample 1

The results in Table 3 demonstrate that the inhibitory effect of M. hyopreparations can be reversed by the acid treatment.

Example 5 Effect of Acid Treatment on Bacterial Antigen-AntibodyComplexes

To demonstrate the effect of acid treatment on bacterialantigen-antibody complexes a component (Leptospirae tarassovi) of acanine vaccine against leptospirosis was quantified in a sandwich ELISAcomparable to that of the PCV-2 ELISA in the presence and absence ofartificially added polyclonal canine serum antibodies containing L.tarassovi specific antibodies, with or without acid treatment.

TABLE 4 Detection of bacterial antigen and antigen- antibody complexesby ELISA a) Treatment A B C D Inc. of polycl. Porc. − + − +anti-tarassovi antibodies Acid treatment − − + + ELISA (% of control)100 50.9 ± 2.1 93.8 ± 1.8 99.2 ± 3.6 a) L. tarassovi antigen wasquantified by ELISA essentially as described in Example 1 usingtarassovi specific monoclonal antibodies (A). Canine serum containingpolyclonal anti-tarassovi antibodies and antigen were incubated prior toantigen quantification by ELISA (B, D). Acid treatment was performed asdescribed in Example 4. ELISA results were expressed as % of the controlexperiment (A). Values are the mean ± Std of duplicates.

These results demonstrate that that the inhibitory affect of canineserum antibodies on the quantification of bacterial vaccine componentsby ELISA can be reversed by an acid treatment.

Example 6 Parameters Affecting the Acid Treatment

5.1. Capacity of Different Acids and Base

The effect of several acids and base on the determination of the antigencontent in vaccine preparations are summarized in Table 5.

TABLE 5 Treatment with different acids and sodium hydroxide Citric acidAcetic acid Sulfuric acid Hydrochloric acid Sodium hydroxideTreatment^(a)) recovery (%) recovery (%) recovery (%) recovery (%)recovery (%) ELISA^(b)) 97^(c)) 94 98 128 0^(d)) ^(a))Bivalent vaccinepreparations were treated as described in Example 4 with the exceptionthat all acids had been adjusted to pH 1.5 andsodium hydroxide to pH13.5 ^(b))PCV concentrations were determined by ELISA as described inExample 1 ^(c))recovery is expressed as the percentage of theconcentration measured as compared to the concentration withouttreatment ^(d))No detectable PCV by ELISA

These results demonstrated that the inhibitory effect of M hyo isindependent from the type of acid used.

Treatment with sodium hydroxide at pH 13.5 completely abolished thedetection of PCV-2 antigen by ELISA. This is likely due to a destructionof the PCV-2 epitopes recognized by the monoclonal antibodies used inthe ELISA.

5.2. Influence of Acid Concentration

The influence of acid concentration was tested by varying the ratio(v/v) between 0.1M citric acid and monovalent or bivalent vaccine. SeeFIG. 2, where a) Recovery (%) based on untreated monovalent vaccinemeasured by ELISA as described in Example 1.

b) Ratio (v/v) between acid and vaccine during the acid treatment asdescribed in Example 4. The results in FIG. 2 demonstrate that a lowrecovery rate of a bivalent vaccine can be overcome by acid treatmentwith a ratio≧25.

5.3 Influence of Treatment Time

The influence of treatment time is shown in FIG. 3, where a) Units/mldetermined by ELISA as described in Example 1. The results indicate thata treatment 8 hours is necessary for a sufficient degree of inhibitionreversal.

5.4. Influence of pH

The influence of pH was assessed by acid treatments at different pH's.In FIG. 4,

a) 5 independent PCV batches were each mixed with one out of two (A, B)independent m hyo batches. All 10 preparations were acid treated asdescribed in Example 4 either with 0.1M citric acid or with 0.1M citricacid adjusted with sodium acetate to pH 2, 3, 4, or 5, or with buffer(C=control). The concentrations are expressed as percentages of theconcentrations obtained by the standard treatment (0.1M citric acid, pH1.5). Data are shown as the mean±Std of the 5 PCV batches combinedeither with Mhyo batch A or B.

These data show that acid treatment at a pH≦3 results in a significantreversal of the inhibitory effect of M. hyo preparations.

The invention claimed is:
 1. A composition comprising a porcinecircovirus type 2 (PCV-2) antigen and a Mycoplasma hyopneumoniae (M.hyo) antigen; wherein the M. hyo antigen originates from mediacomprising serum that also contains an antibody that is capable ofbinding to the PCV-2 antigen; wherein the M. hyo antigen has beenseparated from said antibody; and wherein said composition is obtainedby the method of: A. separating the M. hyo antigen from said antibody byeither centrifugation or an immuno-depletion step; wherein the M. hyoantigen is separated from said antibody; and B. mixing the PCV-2 antigenwith the M. hyo antigen separated from said antibody.
 2. A vaccinecomprising the composition of claim 1; wherein the PCV-2 antigen is aPCV-2 ORF2 protein, the M. hyo antigen is a bacterin, or both the PCV-2antigen is a PCV-2 ORF2 protein and the M. hyo antigen is a bacterin. 3.A mixture comprising a porcine circovirus type 2 (PCV-2) antigen and aMycoplasma hyopneumoniae (M hyo) antigen; wherein the M hyo antigenoriginates from media comprising serum that also contains an antibodythat is capable of binding to the PCV-2 antigen; and wherein the M hyoantigen had been separated from said antibody prior to mixing the M hyoantigen with the PCV-2 antigen to form said mixture.
 4. The vaccine ofclaim 2 wherein the M. hyo antigen is an M hyo bacterin and the PCV-2antigen is a PCV-2 ORF2 protein.
 5. The composition of claim 1, whereinsaid separating of the M. hyo antigen from said antibody is performed byan immuno-depletion step.
 6. The composition of claim 5, wherein saidimmuno-depletion step is performed with a Protein-G ligand or aProtein-A ligand.
 7. The composition of claim 6, wherein the Protein-Gligand or the Protein-A ligand is bound to a solid phase.
 8. Thecomposition of claim 5, wherein said immuno-depletion step is performedwith the Protein-A ligand.
 9. The composition of claim 8, wherein theProtein-A ligand is bound to a solid phase.
 10. A method for determiningthe antigen content of a porcine circovirus type 2 (PCV-2) antigen in amixture comprising the PCV-2 antigen and a Mycoplasma hyopneumoniae (Mhyo) antigen; wherein the M. hyo antigen originates from mediacomprising serum that also contains an antibody that is capable ofbinding to the PCV-2 antigen; wherein the method comprises the steps of:A. separating the M hyo antigen from said antibody; B. mixing the M. hyoantigen with the PCV-2 antigen to form a mixture; and C. determining theantigen content of the PCV-2 antigen in the mixture by means of animmunoassay.
 11. The method of claim 10, wherein the method is a potencytest of a combination vaccine.
 12. The method of claim 10, wherein saidseparating is performed by centrifugation or by an immune-depletionstep.
 13. The method of claim 12, wherein said separating is performedby immune-depletion, comprising the steps of: (i) capturing saidantibody with a ligand that exhibits an affinity for said antibody,whereby a ligand-antibody complex is formed; and (ii) separating theligand-antibody complex from the M. hyo antigen.
 14. The method of claim13, wherein the ligand is bound to a solid phase.
 15. The method ofclaim 10, wherein the PCV-2 antigen is a PCV-2 ORF2 protein.
 16. Amethod for preparing a composition comprising a porcine circovirus type2 (PCV-2) antigen and a Mycoplasma hyopneumoniae (M hyo) antigen,wherein the M. hyo antigen originates from media comprising serum thatalso contains an antibody that is capable of binding with the PCV-2antigen, said method comprising the steps of: A. separating the M hyoantigen from said antibody; and B. mixing the M. hyo antigen with thePCV-2 antigen.
 17. The method of claim 16, wherein said separating isperformed by centrifugation or by an immune-depletion step.
 18. Themethod of claim 17, wherein said separating is performed byimmune-depletion, comprising the steps of: (i) capturing said antibodywith a ligand that exhibits an affinity for said antibody, whereby aligand-antibody complex is formed; and (ii) separating theligand-antibody complex from the M. hyo antigen.
 19. The method of claim18, wherein the ligand is bound to a solid phase.
 20. The method ofclaim 19 wherein the PCV-2 antigen is a PCV-2 ORF2 protein.
 21. Themethod of claim 15, wherein the method is a potency test of acombination vaccine.
 22. The method of claim 15, wherein the M. hyoantigen is an M hyo bacterin.
 23. The method of claim 13, wherein saidimmuno-depletion step is performed with a Protein-G ligand or aProtein-A ligand.
 24. The method of claim 23, wherein saidimmuno-depletion step is performed with a Protein-A ligand.
 25. Themethod of claim 24, wherein the Protein-A ligand is bound to a solidphase.
 26. The method of claim 20, wherein the M hyo antigen is an M hyobacterin.
 27. The method of claim 18, wherein the ligand is Protein-G orProtein-A.
 28. The method of claim 27, wherein the ligand is Protein-A.29. A vaccine comprising the composition of claim 1, wherein the PCV-2antigen is an inactivated PCV-2.